TheraVet: Commercial Launch of BIOCERA-VET® for Canine Osteosarcoma in Belgium, France and The Netherlands
09 Décembre 2021 - 7:30AM
Business Wire
- Start of commercialization, as planned, of BIOCERA-VET®
Osteosarcoma, a game-changer in the palliative management of bone
cancer in companion animals
- Limb-sparing BIOCERA-VET® cementoplasty approach
significantly relieves pain and improves quality of life of dogs
with bone cancer
Regulatory News:
TheraVet (ISIN: BE0974387194 - ticker: ALVET), a
pioneering company in the management of osteoarticular diseases in
companion animals, announces today the commercial launch of
BIOCERA-VET® - Osteosarcoma in Belgium, France and The
Netherlands.
Canine osteosarcoma is the most frequent and most aggressive dog
primary bone cancer affecting more than 30.000 patients per year in
Europe and in United-States. Currently, osteosarcoma management is
mainly performed by amputation or limb-sparing surgeries associated
with chemotherapy. Unfortunately these invasive approaches are not
always the optimal option for the pets and the owners, looking for
more palliative and qualitative alternatives such as BIOCERA-VET® -
Osteosarcoma used in a minimally invasive surgical technique
consisting in cementing the tumoral site with BIOCERA-VET®.
With this new step, TheraVet is pursuing, as planned, its
commercial expansion strategy with the launch of the second product
of its bone substitute product line, BIOCERA-VET® - Osteosarcoma,
in Belgium, France and in The Netherlands.
Based on promising efficacy and safety results disclosed earlier
this year, BIOCERA-VET®- Osteosarcoma represents a game-changer
option in the management of canine osteosarcoma.
Enrico Bastianelli, Chief Executive Officer of TheraVet,
concludes: “Based on solid clinical evidences, it can now be
said that BIOCERA-VET® - Osteosarcoma will meet an important need
in the palliative management of canine osteosarcoma by relieving
pain and improving the quality of life of our beloved pets through
a minimally invasive approach. We are therefore very happy to make
it available.”
About TheraVet SA TheraVet is a veterinary biotechnology
company specialising in osteoarticular treatments for animals. The
Company develops targeted, safe and effective treatments to improve
the quality of life of pets suffering from osteoarticular diseases.
For pet owners, the health of their pets is a major concern and
TheraVet’s mission is to address the need for innovative and
curative treatments. TheraVet works closely with international
opinion leaders in order to provide a more effective response to
ever-growing needs in the field of veterinary medicine. TheraVet is
listed on Euronext Growth® Paris et Brussels, its head office is in
Gosselies, Belgium, and it has a subsidiary in the US.
For more information, visit the TheraVet website or follow us on
LinkedIn / Facebook / Twitter.
For more information about BIOCERA-VET®- Osteosarcoma, visit
www.bioceravet.be, www.bioceravet.fr and www.bioceravet.nl.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211208006112/en/
TheraVet Sabrina Ena Chief Operating Officer
sabrina.ena@thera.vet +32 (0)71 96 00 43
Julie Winand Chief Corporate Officer julie.winand@thera.vet
NewCap Investor Relations and Financial Communications
Louis Tilquin / Olivier Bricaud theravet@newcap.eu +33 (0)1 44 71
94 94
Press Relations Arthur Rouillé / Ambre Delval theravet@newcap.eu
+33 (0)1 44 71 00 15
TheraVet (EU:ALVET)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
TheraVet (EU:ALVET)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024